Drugs

Papers
(The H4-Index of Drugs is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression449
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments441
Bimekizumab for the Treatment of Psoriasis321
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations316
Targeting DNA Damage Response Deficiency in Thoracic Cancers227
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema190
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”173
Aprocitentan: First Approval158
Eftrenonacog Alfa: A Review in Haemophilia B137
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments134
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences127
Epcoritamab: First Approval126
Spesolimab for the Treatment of Generalized Pustular Psoriasis121
Teclistamab: First Approval117
Vorasidenib: First Approval116
New Therapies on the Horizon for Primary Biliary Cholangitis111
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using108
Senaparib: First Approval107
Upacicalcet: First Approval106
Cosibelimab: First Approval106
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?104
Repotrectinib: First Approval103
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer96
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine96
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies94
Olipudase Alfa: First Approval93
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial92
Ivarmacitinib Sulfate: First Approval92
Atogepant: First Approval92
Drugs in Development to Manage Acute Pain90
Lenacapavir: First Approval86
Danicopan: First Approval83
Acoltremon: First Approval82
Androgenetic Alopecia: Therapy Update82
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure82
Finerenone: First Approval82
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis81
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?80
Cancer Pain Treatment Strategies in Patients with Cancer77
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema76
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection75
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids75
Olverembatinib: First Approval73
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?73
Mosunetuzumab: First Approval73
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology72
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections72
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification72
Correction to: Tapinarof Cream 1%: First Approval70
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A70
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes68
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis67
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough67
Correction to: Prevention and Treatment of Monkeypox66
Tovorafenib: First Approval65
Dorzagliatin: First Approval65
The Place of Cannabinoids in the Treatment of Gynecological Pain65
Sunvozertinib: First Approval64
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer64
Pozelimab: First Approval62
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options60
0.03361701965332